GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
A

AP Biosciences 6945.TWO · TWD

Health Care · Taipei Exchange · 🇹🇼 Taiwan

Compare

112.00

0.00%

Close of 9 Nov 2026, in TWD

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

At a glance

Figures in TWD, from our data supplier.

FY2025

Revenue

—

FY2020FY2025

Net income

−TWD 444.8m

FY2020FY2025

Free cash flow

−TWD 377.3m

FY2020FY2025

Shareholders' equity

TWD 1.27bn

FY2020FY2025

Income statement

Fiscal years

FY2025FY2024FY2023FY2022FY2021FY2020
Revenue——TWD 32.3m—TWD 7.0mTWD 137.6m
Research and developmentTWD 369.8mTWD 365.4mTWD 336.6mTWD 262.7mTWD 173.8mTWD 66.8m
Operating income−TWD 456.4m−TWD 439.1m−TWD 347.5m−TWD 288.5m−TWD 186.7mTWD 45.0m
Net income−TWD 444.8m−TWD 422.7m−TWD 339.3m−TWD 288.5m−TWD 187.6mTWD 41,745
Diluted earnings per share-5.23-4.97-5.24-5.10-3.890.00

Balance sheet

At each fiscal year end

FY2025FY2024FY2023FY2022FY2021FY2020
Total assetsTWD 1.37bnTWD 1.73bnTWD 890.8mTWD 1.10bnTWD 579.3mTWD 652,024
Cash and short-term investments—TWD 1.54bnTWD 740.0mTWD 1.08bnTWD 557.1mTWD 630,724
Total liabilitiesTWD 94.2mTWD 104.4mTWD 106.7mTWD 4.5mTWD 21.1mTWD 9,162
Debt—TWD 70.9mTWD 82.1m———
Shareholders' equityTWD 1.27bnTWD 1.62bnTWD 784.1mTWD 1.10bnTWD 558.2mTWD 642,862
Shares outstanding85m85m65m57m48m48m

Cash flow

Fiscal years

FY2025FY2024FY2023FY2022FY2021FY2020
Cash from operations−TWD 352.1m−TWD 357.9m−TWD 297.6m−TWD 276.0m−TWD 168.7m−TWD 17,046
Capital spending−TWD 25.3m−TWD 5.5m−TWD 35.4m−TWD 2.4m−TWD 4.9m−TWD 7,250
Free cash flow−TWD 377.3m−TWD 363.4m−TWD 333.0m−TWD 278.4m−TWD 173.6m−TWD 24,296

Latest quarters

By quarter end

Jun 2026Mar 2026Dec 2025Sept 2025Jun 2025Mar 2025Dec 2024Sept 2024
Operating income−TWD 165.2m−TWD 94.4m−TWD 101.1m−TWD 156.6m−TWD 198.6m−TWD 79.3m−TWD 205.7m−TWD 102.6m
Net income−TWD 127.3m−TWD 90.0m−TWD 94.1m−TWD 153.0m−TWD 197.7m−TWD 75.7m−TWD 196.5m−TWD 99.7m
Diluted earnings per share-1.31-1.05-1.11-1.80-2.32-0.89-2.31-1.17
Cash from operations−TWD 108.0m−TWD 70.0m−TWD 103.0m−TWD 84.0m−TWD 164.0m−TWD 59.0m−TWD 161.0m−TWD 49.0m
Capital spending−TWD 2.0m−TWD 2.0m−TWD 4.0m−TWD 7.0m−TWD 13.0m−TWD 4.0m−TWD 4.0m−TWD 3.0m
Free cash flow−TWD 110.0m−TWD 72.0m−TWD 107.0m−TWD 91.0m−TWD 177.0m−TWD 63.0m−TWD 165.0m−TWD 52.0m
Total assetsTWD 2.41bnTWD 1.29bnTWD 1.37bnTWD 1.46bnTWD 1.55bn—TWD 1.73bn—
Cash and short-term investments————TWD 1.36bn—TWD 1.54bn—
Debt————TWD 23.3m—TWD 23.3m—
Shareholders' equityTWD 2.33bnTWD 1.20bnTWD 1.27bnTWD 1.34bnTWD 1.46bn—TWD 1.62bn—

Financial ratios

Data as of 29 Sept 2026

FY2025FY2024FY2023FY2022FY2021FY2020
Operating margin——-1077.4%—-2670.1%0.0%
Net margin——-1052.0%—-2682.8%0.0%
Return on equity-35.0%-26.1%-43.3%-26.3%-33.6%6.5%
Return on assets-32.6%-24.5%-38.1%-26.2%-32.4%6.4%
Free cash flow yield-2.7%-3.0%-2.9%-3.5%——
Revenue growth————-94.9%—
Earnings growth5.2%24.6%17.6%53.8%-449509.5%—
Current ratio29.94x39.87x24.80x242.10x26.67x69.01x
Debt to equity—0.01x0.03x———
Equity ratio93.1%94.0%88.0%99.6%96.3%98.6%
Interest coverage-320.49x-266.42x-288.84x———
R&D as a share of sales——1043.6%—2485.5%48.6%
Buybacks as a share of market value-0.1%-31.3%-14.5%———

Growth per year

Compound annual rate

3 years5 years10 years
Operating income16.5%——
Net income15.5%——

Valuation history

At each fiscal year end

FY2025FY2024FY2023
Price to earnings-34.1-10.0-8.9
Price to sales——93.5

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.